MALDI Imaging of 13C6-Glucose Uptake Measured in TCA Metabolites from Glioblastoma Mouse Brain

Posters | 2023 | Bruker | ASMSInstrumentation
MALDI, MS Imaging, Ion Mobility, LC/MS/MS, LC/HRMS, LC/MS, LC/TOF
Industries
Metabolomics, Clinical Research
Manufacturer
Bruker

Importance of the Topic


Understanding metabolic reprogramming in glioblastoma is critical for developing targeted therapies and diagnostics. Spatial mapping of labeled metabolites provides direct insight into regional variations in tumor metabolism and the Warburg effect, revealing how cancer cells fuel growth and resist treatment.

Study Objectives and Overview


  • Visualize in situ uptake of 13C6-glucose in a glioblastoma PDX mouse brain model.
  • Compare TCA cycle activity between tumor and healthy brain regions, as well as dosed versus control tissues.

Methodology


  • Patient-derived xenograft mice received intraperitoneal injections of 13C6-glucose at 0 and 30 minutes, then were sacrificed at 60 minutes.
  • Brain sections were mounted on glass slides and coated with N-(1-naphthyl) ethylenediamine dihydrochloride matrix via an HTX M3+ sprayer.
  • MALDI imaging was performed at 20 µm spatial resolution in negative ion mode.
  • Mass spectra from each pixel underwent segmentation analysis to distinguish healthy versus cancerous and dosed versus control regions.

Instrumentation


  • HTX M3+ sprayer for homogeneous matrix application.
  • timsTOF fleX MALDI-2 mass spectrometer operating in negative polarity.
  • SCiLS Lab 2023a for image segmentation and statistical analysis.
  • MetaboScape 2023a for annotation of metabolite signals.
  • Custom R scripting with the SCiLS REST API to quantify isotopic abundances within a ±15 ppm window.

Key Results and Discussion


  • Segmentation clearly differentiated glioblastoma regions from healthy brain and separated dosed from control tissues.
  • Ion images of M+0 through M+3 isotopologues for lactate, malate, and glutamate confirmed uptake and incorporation of 13C into TCA metabolites.
  • Extracted isotopic ratios revealed downregulated TCA cycle flux in tumor tissue compared to healthy regions.
  • Relative abundances demonstrated strong agreement with independent LC-MS validation.

Benefits and Practical Applications


  • Offers high-resolution spatial tracking of metabolic flux in heterogeneous tumor environments.
  • Enables direct visualization of metabolic differences that may inform personalized treatment planning.
  • Supports QA/QC workflows in pharmaceutical and clinical research by mapping tracer distribution.

Future Trends and Opportunities


  • Combining MALDI imaging with MRI and PET for comprehensive multimodal metabolic profiling.
  • Extending the approach to additional cancer types and metabolic disease models.
  • Developing more sensitive isotopic tracers and advanced machine learning algorithms for image segmentation.

Conclusion


Stable isotope-resolved MALDI imaging provides a robust platform to spatially map glucose-derived metabolite flux in glioblastoma. The presented workflow highlights significant differences in TCA activity between tumor and healthy tissue, laying the groundwork for advanced spatial metabolomics in research and clinical applications.

Content was automatically generated from an orignal PDF document using AI and may contain inaccuracies.

Downloadable PDF for viewing
 

Similar PDF

Tumor heterogeneity of glioblastoma analyzed via SpatialOMx and HiPLEX-IHC MALDI Imaging
Bruker MRMS Applications Handbook